Qube Research & Technologies LTD Y M Abs Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$4.88 - $7.42 $30,495 - $46,367	6,249 New	6,249 $42,000
Q4 2022 Feb 14, 2023	SELL	$3.0 - $15.17 $6,855 - $34,663	-2,285 Reduced 8.09%	25,966 $126,000
Q3 2022 Nov 14, 2022	BUY	$13.96 - $19.67 $394,383 - $555,697	28,251 New	28,251 $407,000
Q1 2022 May 09, 2022	SELL	$6.55 - $17.42 $102,029 - $271,351	-15,577 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$15.51 - $29.31 $241,599 - $456,561	15,577 New	15,577 $253,000
Q2 2021 Aug 13, 2021	SELL	$25.45 - $37.64 $265,519 - $392,698	-10,433 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$29.16 - $51.96 $304,226 - $542,098	10,433 New	10,433 $315,000
Q3 2020 Nov 12, 2020	SELL	$35.13 - $43.62 $460,589 - $571,901	-13,111 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$23.66 - $49.53 $310,206 - $649,387	13,111 New	13,111 $566,000
Q1 2020 May 15, 2020	SELL	$14.39 - $35.8 $109,191 - $271,650	-7,588 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$23.81 - $33.78 $180,670 - $256,322	7,588 New	7,588 $237,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $356M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.